Skip to main content
BioThera Solutions

Full-Spectrum EV Platform. Precision Biomanufacturing from Source to Specification.

BioThera Solutions operates a full-stack extracellular vesicle (EV, exosome) biomanufacturing platform, from upstream isolation to downstream characterization in line with MISEV2023, designed for consistency, traceability and scale. Our current source is plant-derived, and the platform is built to extend to other sources.

What Are Extracellular Vesicles (EVs / Exosomes)?

Extracellular vesicles (EVs/exosomes) are nanoscale, membrane-bound particles naturally released by virtually all cell types as part of normal cellular communication. They range from approximately 30 to 1000 nm in diameter, though EV populations are inherently heterogeneous, and a high-quality preparation will cluster around a defined size peak, typically 30–200 nm for small EVs. They carry a complex molecular cargo, including proteins, lipids, nucleic acids (such as miRNA and mRNA), and bioactive signaling molecules.

EVs are natural, membrane-bound particles that carry proteins, lipids and small RNAs between cells as part of normal cellular communication. This makes EVs an area of substantial scientific and commercial interest across medicine and consumer health.

In skin biology specifically, EVs derived from botanical sources have been studied in the peer-reviewed literature for their potential role in supporting antioxidant activity and skin-conditioning properties in keratinocyte and fibroblast populations. Products made with our material are cosmetics, and no drug or therapeutic claims are made.

Note: The term "exosome" is colloquially used in the broader market but is not precise under current ISEV/MISEV2023 guidelines, which recommend "extracellular vesicle" (EV) as the primary scientific descriptor unless intracellular endosomal origin is experimentally confirmed. BioThera uses "EV" as its primary scientific term. Where our materials, including our Certificates of Analysis, use "exosome", it is for market recognition and discoverability only, not a claim of demonstrated endosomal biogenesis. Under the nomenclature proposed by the ISEV Plant EVs Task Force, our material is a plant-derived nanovesicle (PDNV).

Play with medrag to rotate
  • Phospholipid bilayer

    Lipid membrane defining the EV boundary and enabling cellular uptake.

  • Tetraspanins

    MISEV-designated surface markers mediating EV-cell recognition and uptake.

  • Transmembrane proteins

    Cargo loading and cellular targeting determinants embedded in the bilayer.

  • Biomolecular corona

    Adsorbed proteins forming a dynamic outer shell that shapes how the vesicle interacts with cells.

  • Intraluminal cargo

    Proteins, lipids and nucleic acids carried inside the vesicle, including the bioactive classes described below.

EV composition and corona structure vary by source cell type, isolation method, and biological environment.

How Does BioThera Solutions Manufacture Plant-Derived EVs?

BioThera Solutions uses a standardized, closed-loop biomanufacturing workflow, from upstream sourcing and EV isolation to downstream particle characterization, producing extracellular vesicles to MISEV2023-aligned specifications. The process is engineered for batch-to-batch reproducibility, full traceability, and scalability from research-grade to commercial-grade output.

Our EV isolation and purification process is proprietary and patent pending. Process details are not disclosed publicly. What we can confirm:

  • Designed for reproducibility and scalability from the ground up
  • Every production batch undergoes standardized analytical characterization
  • Material is lyophilized (freeze-dried) with trehalose for room-temperature storage, with a shelf life of 5 years from manufacture
  • Manufacturing trajectory aligned toward GMP and ISO compliance

Our Core Moat

Our process is designed to scale, and we are investing heavily in scaling our operations without compromising the rigour the field requires. Our biomanufacturing workflow is the infrastructure the EV field has been missing: reproducible, standardized, and engineered from the ground up to be source-flexible, starting with plant-derived EVs and built to support applications well beyond our first.

Quality Control Framework

Nanoparticle Tracking Analysis (NTA)

Particle concentration and size distribution measured for every batch, a core method for EV characterization under MISEV2023.

Certificate of Analysis (CoA)

Batch-level documentation issued for every production run.

Storage & Stability

Lyophilized for room-temperature storage and shipping. After reconstitution, material keeps at 4 °C for up to 1 month, or frozen for up to 1 year.

MISEV2023 Characterization

Characterization in line with the Minimal Information for Studies of Extracellular Vesicles (MISEV2023) guidelines published by ISEV.

Stability, Designed Around Each Product Line.

Extracellular vesicles are biological material. Temperature, water and time all work against them, so how a product is stored and shipped is part of its quality, not an afterthought. We design storage and logistics around the needs of each product line.

Storage

Lyophilized, stored at room temperature

Material supplied to our licensee is lyophilized (freeze-dried) in a citrate buffer with trehalose and stored at room temperature, with a shelf life of 5 years from manufacture. Each delivery comes with the Certificate of Analysis for its batch.

Reconstituted

After reconstitution

Each vial is reconstituted with the provided diluent. Once reconstituted, material keeps at 4 °C for up to 1 month, or frozen for up to 1 year. Lyophilization removes nearly all of the water, leaving a dry form that is far easier to store and ship than a liquid preparation.

How freeze-drying works, in plain terms

01

Freeze

The vesicle preparation is frozen solid, locking its water into ice.

02

Remove the ice

Under a deep vacuum, the ice turns straight into vapour without ever melting, and is drawn away. It is the same principle used for many injectable medicines.

03

Seal it dry

What remains is a dry material, sealed against moisture until it is reconstituted.

Why it works

Most of what degrades a biological product over time needs water: chemical breakdown, microbial growth, and particles clumping together. Remove the water and those processes slow dramatically. Lyophilization is carried out under tightly controlled conditions by our scientific team.

Why Source Matters: Plant and Mammalian EVs

Extracellular vesicles can come from many biological sources, and each suits different applications. Our current platform uses plant-derived vesicles, which bring real advantages in scale and cost. As we grow, our research extends to animal-derived sources, including human stem cell-derived vesicles, for applications where their biology is the better fit.

Renewable SourceNo Donor MaterialLow-Cost Scale

Cross-Kingdom Biological Communication

The capacity of plant-derived EVs to interact with and influence mammalian cellular processes represents an emerging and scientifically important area of EV research. This cross-kingdom biological communication underpins our first EV source, and informs how we evaluate every application we build on the platform.

01

Plant-derived: built for scale

Abundant, renewable biomass and no cell culture make production simpler and lower in cost, with no animal or human donor material required.

02

Plant-derived: a clean starting point

Plant sources reduce the contamination and donor-variability risks of mammalian cell culture, and the long use of botanical actives in cosmetics provides a well-characterized safety baseline for topical use.

03

Mammalian-derived: human-relevant biology

Vesicles from mammalian cells, including human stem cells, carry signalling molecules shaped by human tissue biology, and they are the most studied source in therapeutic research.

04

Choosing by application

No single source is best for every use. We match the source to the application, and our manufacturing and characterization expertise carries across sources.

What Bioactive Cargo Do Plant-Derived EVs Carry?

Proteomics characterization of BioThera's current plant-derived EV material identified proteins in three classes: antioxidant-associated, skin-soothing-associated and skin-conditioning-associated. This protein composition is consistent with the profile of Aloe barbadensis described across decades of peer-reviewed literature.

Proteomics analysis of our plant-derived EVs identified proteins associated with three distinct bioactive classes.

Antioxidant Payload

Proteins associated with antioxidant activity, identified by proteomics. Studied in cell-based research for their association with cellular defense mechanisms against oxidative stress in skin cell populations.

Skin-Soothing Bioactive Fraction

Signaling-associated proteins identified by proteomics: studied in cell-based research for their association with skin-soothing and calming properties in keratinocyte and fibroblast populations.

Skin-Renewal Bioactive Fraction

Growth factor-associated proteins identified by proteomics: studied in cell-based research for their role in supporting skin cell renewal and conditioning processes.

Bioactive payload characterization conducted by proteomics and in line with MISEV2023 guidelines. No therapeutic claims are made. Products made with our material are cosmetics under Canada's Cosmetic Regulations (C.R.C., c. 869).

One platform. Many applications.

The same isolation and characterization workflow supplies every application built on the platform. See what it supplies, which application areas it serves, and how far each one has actually gone.

See the applications

How Do Plant-Derived EVs Interact with Human Skin?

Current scientific evidence supports EV surface and epidermal interaction as the primary mechanism by which topically applied plant-derived EVs may influence skin biology. BioThera Solutions presents an evidence-stratified model distinguishing well-supported surface interactions from plausible follicular routes, while noting that further research is required to demonstrate passive penetration of intact EV-sized particles (30–1000 nm) across the stratum corneum.

Extracellular vesicles are proposed to interact with human skin through multiple pathways, each associated with a distinct level of experimental support. This model distinguishes well-supported surface and epidermal interactions from plausible follicular penetration. Trans-stratum corneum passive diffusion of intact EV-sized particles (30–1000 nm) remains an area where further research is required to demonstrate penetration across the SC. No mechanism depicted is clinically confirmed.

Pathway Evidence Levels

✅Surface / epidermal interaction
⚠️Follicular route (plausible)
❌Trans-SC diffusion (further research required)
Most EVs measure 100–150 nm · rigid particles of 20–200 nm stay in the outer stratum corneum · whether deformable EVs differ is not yet known

Evidence-stratified pathway model: no mechanism is clinically confirmed. This illustration maps proposed interaction pathways by level of experimental support. Surface and stratum corneum activity is the best supported: in human skin samples, topically applied EVs stayed largely in the stratum corneum, with less than 1% of the applied signal crossing the skin over 24 hours. Follicular penetration is a documented route for nanoparticles and a plausible one for EVs, not yet shown for them. Passive diffusion of intact EVs across the stratum corneum has not been demonstrated; reaching the dermis takes a procedure such as microneedling, which changes the product's safety requirements and, in Canada, its regulatory category.

Anatomical accuracy & site-of-effect framing. Layer proportions are calibrated to H&E histological reference standards. The epidermis is rendered at 3× its true relative scale. Vasculature is shown in longitudinal view; hair follicle, sebaceous gland, eccrine sweat gland, and dermal innervation are anatomically positioned. In the animation, most EVs settle in the stratum corneum and a small share follows the hair follicle; none crosses into the living epidermis or the dermis, reflecting current human skin evidence. The effects of a topical EV product are therefore framed at the skin surface and upper epidermis; any effect on deeper layers would be indirect, through signalling from the surface, and has not been demonstrated.

BioThera Solutions

A fully integrated extracellular vesicle company, from research and intellectual property to manufacturing, with a process designed to scale. Extracellular vesicles (EVs/exosomes) are among biology's most promising delivery systems, and we are building the infrastructure the field has been missing.

Ottawa, Ontario, Canada
477-150 Louis-Pasteur Private Ottawa, Ontario K1N 9B4 Canada
Add BioThera Solutions as a preferred source on Google

© 2026 BioThera Solutions Inc. All rights reserved.

For informational purposes only. Nothing on this website is medical advice. BioThera develops and manufactures characterized extracellular vesicles (exosomes) and, for cosmetic applications, licenses its technology exclusively to Vesera™, a skincare company and BioThera subsidiary. Vesera™ products are cosmetics and are not intended to diagnose, treat, cure, or prevent any disease. BioThera does not sell products to consumers, and its work on therapeutic applications is research only.